Full name
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
NCT Number
NCT04718389
Geography
US
Non-US
Locations
Australia, Austria, Canada, Finland, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Norway, Portugal, Puerto Rico, Slovenia, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Primary Endpoints
Annualized rate of clinically significant exacerbations over 52 weeks
External Link
https://clinicaltrials.gov/study/NCT04718389
Order
2
Disease
Version
Phase
3